Pharmesis International Ltd
SGX:BFK
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Pharmesis International Ltd
Cash from Operating Activities
Pharmesis International Ltd
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
P
|
Pharmesis International Ltd
SGX:BFK
|
Cash from Operating Activities
¥2m
|
CAGR 3-Years
-33%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-16%
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Cash from Operating Activities
¥4.8B
|
CAGR 3-Years
20%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Cash from Operating Activities
¥11.2B
|
CAGR 3-Years
107%
|
CAGR 5-Years
27%
|
CAGR 10-Years
17%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Cash from Operating Activities
¥4.6B
|
CAGR 3-Years
13%
|
CAGR 5-Years
4%
|
CAGR 10-Years
8%
|
|
|
Zhejiang Nhu Co Ltd
SZSE:002001
|
Cash from Operating Activities
¥8.8B
|
CAGR 3-Years
26%
|
CAGR 5-Years
23%
|
CAGR 10-Years
25%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Cash from Operating Activities
¥4.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
171%
|
CAGR 10-Years
N/A
|
|
Pharmesis International Ltd
Glance View
Pharmesis International Ltd. is an investment holding company, which engages in the research, development, production, sale, and marketing of medicine and medicine formulated products for the treatment of illnesses relating to the liver and gall bladder. The company is headquartered in Chengdu, Sichuan. The company went IPO on 2004-10-06. The firm is a pharmaceutical company engaged in the manufacturing of pharmaceutical products, including western medicine in the form of tablets and granules, among others, and traditional Chinese medicine (TCM) formulated products for the treatment of illnesses relating to the liver and gall bladder. The company operates in three segments: Western drugs, which refers mainly to chemically formulated drugs marketed under the Kinna brand; TCM formulated drugs, which includes TCM marketed under the Longlife brand, and Distribution, which includes agency products and internally manufactured products marketed through the distribution arm. Its main products are ATT, Gulin Gansu and Er Ding granules. Its subsidiary, Chengdu Kinna Pharmaceutical Co., Ltd, is engaged in the development, manufacture, packaging and sale of western medicines and health tonic products.
See Also
What is Pharmesis International Ltd's Cash from Operating Activities?
Cash from Operating Activities
2m
CNY
Based on the financial report for Dec 31, 2025, Pharmesis International Ltd's Cash from Operating Activities amounts to 2m CNY.
What is Pharmesis International Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
-16%
The average annual Cash from Operating Activities growth rates for Pharmesis International Ltd have been -33% over the past three years , 3% over the past five years , and -16% over the past ten years .
